Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF.
Publication
, Journal Article
Pohlman, FW; McGee, KS; McKellar, MS
Published in: Open Forum Infect Dis
August 2021
We report a case of substantial weight gain in a virologically suppressed patient with HIV after changing his antiretroviral therapy from efavirenz/emtricitabine/tenofovir DF to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide with subsequent rapid weight loss upon switching back. The role of antiretrovirals in weight gain and loss and patient- and HIV-specific factors are discussed.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Open Forum Infect Dis
DOI
ISSN
2328-8957
Publication Date
August 2021
Volume
8
Issue
8
Start / End Page
ofab403
Location
United States
Related Subject Headings
- 3207 Medical microbiology
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Pohlman, F. W., McGee, K. S., & McKellar, M. S. (2021). Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF. Open Forum Infect Dis, 8(8), ofab403. https://doi.org/10.1093/ofid/ofab403
Pohlman, F Will, Kara S. McGee, and Mehri S. McKellar. “Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF.” Open Forum Infect Dis 8, no. 8 (August 2021): ofab403. https://doi.org/10.1093/ofid/ofab403.
Pohlman FW, McGee KS, McKellar MS. Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF. Open Forum Infect Dis. 2021 Aug;8(8):ofab403.
Pohlman, F. Will, et al. “Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF.” Open Forum Infect Dis, vol. 8, no. 8, Aug. 2021, p. ofab403. Pubmed, doi:10.1093/ofid/ofab403.
Pohlman FW, McGee KS, McKellar MS. Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF. Open Forum Infect Dis. 2021 Aug;8(8):ofab403.
Published In
Open Forum Infect Dis
DOI
ISSN
2328-8957
Publication Date
August 2021
Volume
8
Issue
8
Start / End Page
ofab403
Location
United States
Related Subject Headings
- 3207 Medical microbiology
- 3202 Clinical sciences